Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.

Zacks Investment Research • Nov 14, 2025

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

PALO ALTO, Calif. , Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025.

PRNewsWire • Nov 13, 2025

Kodiak Sciences to Present at Upcoming Investor Conferences

PALO ALTO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that Victor Perlroth, M.D.

PRNewsWire • Nov 12, 2025

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

Meaningful vision gains are rapidly achieved as early as week 4 and showed continued improvement in best corrected visual acuity (BCVA) through week 20, with more than half of patients achieving improvement of 3-lines or more on the eye chart (≥15 letter gain). ≥90% of patients in the top two dose levels achieved and sustained real dryness of the retina, as demonstrated by absence of intraretinal fluid (IRF) as well as subretinal fluid (SRF), key markers of disease activity.

PRNewsWire • Nov 5, 2025

The Big 3: GOOGL, KOD, FTK

Alphabet (GOOGL) spiked into its earnings this week, and @stockstotrade's Tim Bohen believes the Google parent company has much more room to run. He explains his bull case that rides on A.I.

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain) A single dose of KSI-101 resulted in the majority of patients achieving resolution of intra-retinal and sub-retinal fluid and over 90% of patients achieved retinal dryness by Week 8 The Phase 3 PEAK and PINNACLE studies of KSI-101 are actively enrolling, testing the top two dose levels (5 mg and 10 mg) in patients with MESI PALO ALTO, Calif. , Sept. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today new data from the APEX study of KSI-101 presented at the Retina Society 58th Annual Scientific Meeting in Chicago, Illinois.

PRNewsWire • Sep 15, 2025

Why Is Kodiak Sciences (KOD) Down 1.2% Since Last Earnings Report?

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 12, 2025

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

PALO ALTO, Calif. , Sept. 2, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced participation in two upcoming scientific meetings:  The 25th EURetina Congress and The Retina Society 58th Annual Scientific Meeting.

PRNewsWire • Sep 2, 2025

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

On the latest edition of CNBC's “Mad Money Lightning Round,” Jim Cramer called Kodiak Sciences Inc. KOD is a “pure spec” stock.

Benzinga • Aug 27, 2025

Harbour BioMed Reports 2025 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its interim results for the six months ended June 30, 2025.

PRNewsWire • Aug 27, 2025